Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | PYGL | P06737 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 4/20 | 0.54 |
| ▸ | GABRD | O14764 | 4/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.54 |
| ▸ | GABRE | P78334 | 4/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4801726 | 0.89 | NR4A2 (0.60) | NR4A2F7F3 | |
| SCHEMBL5309810 | 0.86 | NR4A2 (0.72) | NR4A2F7F3PYGLGABRA1 | |
| SCHEMBL404920 | 0.86 | LMNA (0.61) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL13013297 | 0.85 | NR4A2 (0.74) | NR4A2F7F3PYGLGABRP | |
| SCHEMBL1993247 | 0.84 | GABRA1 (0.67) | NR4A2GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL1994694 | 0.84 | ALDH1A1 (0.58) | GABRA1GABRB1GABRA3GABRB2 | |
| SCHEMBL5912666 | 0.83 | F7 (0.56) | NR4A2F7F3PYGLGABRP | |
| SCHEMBL5912662 | 0.83 | F7 (0.56) | NR4A2F7F3PYGLGABRP | |
| SCHEMBL13727294 | 0.83 | LMNA (0.64) | NR4A2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL16765425 | 0.82 | NR4A2 (0.61) | NR4A2F7F3PYGLGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011112731-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2324029-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-7446122-B2 | Substituted indole derivatives | CEPHALON, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7314886-B2 | Tetrahydropyrano-indole derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | NR4A2 2417/4885F7 4133/4885F3 2868/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | NR4A2 961/4885F7 3530/4885F3 3755/4885 |
| US-20100120741-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | NR4A2 755/4885F7 2622/4885F3 425/4885 |
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | NR4A2 755/4885F7 2622/4885F3 425/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | NR4A2 755/4885F7 2622/4885F3 425/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | NR4A2 3856/4885F7 3293/4885F3 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.